Thomas Steyer’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-450,000
| Closed | -$30.6M | – | 317 |
|
|
2022
Q3 | $30.6M | Buy |
+450,000
| New | +$24.8M | 0.17% | 87 |
|
|
2022
Q2 | – | Sell |
-169,458
| Closed | -$5.87M | – | 329 |
|
|
2022
Q1 | $5.87M | Buy |
169,458
+83,004
| +96% | +$2.48M | 0.03% | 178 |
|
|
2021
Q4 | $2.53M | Buy |
+86,454
| New | +$2.68M | 0.01% | 205 |
|
|
2020
Q4 | – | Sell |
-600,000
| Closed | -$33.1M | – | 157 |
|
|
2020
Q3 | $33.1M | Buy |
+600,000
| New | +$38.1M | 0.23% | 75 |
|
|
2020
Q1 | – | Sell |
-750,000
| Closed | -$59.6M | – | 122 |
|
|
2019
Q4 | $59.6M | Sell |
750,000
-862,069
| -53% | -$51.1M | 0.4% | 48 |
|
|
2019
Q3 | $78.2M | Buy |
1,612,069
+487,069
| +43% | +$25.4M | 0.59% | 39 |
|
|
2019
Q2 | $59.2M | Sell |
1,125,000
-375,000
| -25% | -$21.6M | 0.38% | 53 |
|
|
2019
Q1 | $79.4M | Buy |
1,500,000
+50,000
| +3% | +$2.46M | 0.6% | 43 |
|
|
2018
Q4 | $59.5M | Buy |
1,450,000
+80,000
| +6% | +$3M | 0.44% | 44 |
|
|
2018
Q3 | $52.1M | Buy |
1,370,000
+185,000
| +16% | +$8.19M | 0.31% | 50 |
|
|
2018
Q2 | $53.6M | Buy |
+1,185,000
| New | +$54M | 0.33% | 50 |
|
|
2018
Q1 | – | Sell |
-340,000
| Closed | -$13.4M | – | 102 |
|
|
2017
Q4 | $13.4M | Buy |
+340,000
| New | +$12.7M | 0.11% | 62 |
|
Other funds holding GBT
Thomas Steyer's GBT Position: Q4 2022 in Review
Thomas Steyer sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 450,000 shares — an estimated $30.6M sold.
Thomas Steyer first reported a position in GBT in Q4 2017 and held it in 12 quarters. The position peaked at $79.4M in Q1 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Thomas Steyer reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Thomas Steyer sold 450,000 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $30.6M.
- Thomas Steyer first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
- Thomas Steyer's Global Blood Therapeutics, Inc. position peaked at $79.4M in Q1 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.